Outcome of Chilean patients with lupus nephritis and response to intravenous cyclophosphamide

Journal of Clinical Rheumatology

Volumn 9, Issue 1, 2003, Pages 7-14

  Velásquez, Ximena ^a   Verdejo, Ulises ^a   Massardo, Loreto ^a   Martínez, María Eugenia ^a,b   Arriagada, Sonia ^a   Rosenberg, Helmar ^a   Valdivieso, Andrés ^a   Jacobelli, Sergio ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b HOSPITAL DR SÓTERO DEL RÍO   (Chile)

Author keywords

IV cyclophosphamide; Lupus nephropathy treatment; Prognosis; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; METHYLPREDNISOLONE; STEROID;

ADOLESCENT; ADULT; AGE; AGED; AMENORRHEA; ARTICLE; AVASCULAR NECROSIS; BOLUS INJECTION; CHILE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG FATALITY; DRUG TOLERABILITY; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPOGAMMAGLOBULINEMIA; INFECTION; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; OLIGOSPERMIA; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; REGISTER; RETROSPECTIVE STUDY; SCHOOL CHILD; SHORT COURSE THERAPY; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

EID: 0037331088     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RHU.0000049711.14038.9F     Document Type: Article

References (40)

1. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991;34:945-90.
2. Bansal VK, Beto JA. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis 1997;29:193-9.
3. Cameron J. Lupus nephritis. J Am Soc Nephrol 1999;10:413-24.
4. Ortmann R, Klippel J. Update on cyclophosphamide for systemic lupus erythematosus. Rheum Dis Clin North Am 2000;26:363-75.
5. Manzi S. Systemic lupus erythematosus. C. Treatment. In: Klippel J, editor. Primer on the rheumatic diseases. 12th edition. Atlanta: Arthritis Foundation; 2001. p. 346-52.
6. Ward M. Outcomes of renal transplantation among patients with end-stage renal disease caused by lupus nephritis. Kidney Int 2000;57: 2136-43.
7. Sessoms S, Kovarski J. Monthly intravenous cyclophosphamide in the treatment of severe systemic lupus erythematosus. Clin Exp Rheumatol 1984;2:247-51.
8. Austin H, Klippel J, Balow J, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314: 614-49.
9. Boumpas D, Austin H, Vaughn E, et al. Controlled trial for pulse methylprednisolone versus two regimens of cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5.
10. Levey AS, Lan SP, Corwin HL, et al. Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide. Ann Intern Med 1992;116: 114-23.
11. Golbus J, McCune WJ. Lupus nephritis. Classification, prognosis, immunopathogenesis and treatment. Rheum Dis Clin North Am 1994;20:213-42.
12. Gourley MF, Austin HA III, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996;125:549-57.
13. Wallace DH, Hahn BH, Klippel JH. Lupus nephritis. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. Pennsylvania: Williams & Wilkins; 1997. p. 1053-65.
14. Illei G, Austin H, Crane M, et al. Combination therapy with pulse cyclophosphamide plus methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135:296-8.
15. Bakir AA, Levy PS, Dunea G. The prognosis of lupus nephritis in African-Americans: a retrospective analysis. Am J Kidney Dis 1994;24: 159-71.
16. Belmont H, Storch M, Buyon J, et al. New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive treatment. Lupus 1995;4:104-8.
17. Conlon PJ, Fischer CA, Levesque MC, et al. Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis. Clin Nephrol 1996;46: 170-5.
18. Dooley MA, Hogan S, Jennette C, et al. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int 1997;51:1188-95.
19. D'Cruz D, Cuadrado MJ, Mujic F, et al. Immunosuppressive therapy in lupus nephritis. Clin Exp Rheumatol 1997;15:275-82.
20. Lewis EJ. The treatment of lupus nephritis: revisiting Galen. Ann Intern Med 2001;135: 296-8.
21. Reveille JD, Bartolucci A, Alarcón GS. Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum 1990;33:37-48.
22. Huong DL, Papo T, Beaufils H, et al. Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center. Medicine (Baltimore) 1999;78:148-66.
23. Rus V, Hochberg M. The epidemiology of systemic lupus erythematosus. In: Wallace D, Hahn B, editors. Dubois' lupus erythematosus. Philadelphia: Lippincott, Williams & Wilkins; 2002. p. 65-86.
24. McCune W, Riskalla M. Immunosuppressive drug therapy. In: Wallace D, Hahn B, editors. Dubois' lupus erythematosus. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 1195-217.
25. Sesso R, Monteiro M, Sato E, et al. A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis. Lupus 1994;3:107-12.
26. Massardo L, Martínez ME, Jacobelli S, et al. Survival of Chilean patients with systemic lupus erythematosus. Semin Arthritis Rheum 1994;24:1-11.
27. Massardo L, Jacobelli S. Occasional series: lupus around the world. The Chilean experience of systemic lupus erythematosus. Lupus 1996; 5:175-7.
28. Tan EM, Cohen AS, Fries JE, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
29. Edworthy S, Bloch D, McShane DA. "State Model" for renal function in systemic lupus erythematosus: its value in the prediction of outcome in 292 patients. J Rheumatol 1989;16: 29-35.
30. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
31. Churg J, Bernstein J, Glassock RJ. Renal disease. Classification and atlas of glomerular diseases. 2nd edition. New York: Igaku-Shoin Medical Publishers; 1995.
32. Austin FU, Muenz L, Joyce KM, et al. Prognostic factors in lupus nephritis: contribution of renal histologic data. Am J Med 1983;75:382-91.
33. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
34. Donadio J, Hart G, Bergstralh E, et al. Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus 1995;4: 109-15.
35. Korbet SM, Lewis EJ, Schwartz MM, et al. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group Am J Kidney Dis 2000;35:904-14.
36. Balow J. Choosing treatment for lupus nephritis. Arthritis Rheum 2002;46:1981-3.
37. Massardo L, Martínez M, Baró M, et al. Infecciones en el lupus eritematoso generalizado. Rev Med Chile 1991;119:1115-22.
38. Ciruelo E, de la Cruz J, Lopez I, et al. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis Rheum 1996;39: 2028-34.
39. Ioannidis JP, Boki KA, Katsorida ME, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000;57: 258-64.
40. Houssiau F, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis. The Euro-Lupus Nephritis Trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-31.